<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: AZD1305 is an investigational antiarrhythmic agent for management of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It blocks various cardiac ion currents at different potencies and has atrial-predominant electrophysiological effects </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the electrophysiological and proarrhythmic effects of AZD1305 versus <z:chebi fb="0" ids="4681">dofetilide</z:chebi> in dogs with <z:hpo ids='HP_0011010'>chronic</z:hpo> complete <z:hpo ids='HP_0001678'>atrioventricular block</z:hpo> and myocardial hypertrophic remodeling </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: AZD1305 was administered to anesthetized mongrel dogs before and &gt;2 weeks after the induction of <z:hpo ids='HP_0001678'>atrioventricular block</z:hpo> and ventricular and atrial electrophysiological parameters were assessed </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> dogs, the selective I(Kr) blocker <z:chebi fb="0" ids="4681">dofetilide</z:chebi> was used to examine susceptibility to acquired <z:hpo ids='HP_0001664'>torsades de pointes</z:hpo> in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001678'>atrioventricular block</z:hpo> and for comparison </plain></SENT>
<SENT sid="5" pm="."><plain>At <z:mpath ids='MPATH_458'>normal</z:mpath> sinus rhythm, AZD1305 increased QT and RR intervals from 290±7 to 397±15 ms (+37%, P&lt;0.0001) and from 603±22 to 778±32 ms (+29%, P=0.002), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>In the same animals at <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001678'>atrioventricular block</z:hpo>, AZD1305 increased the QT interval from 535±28 to 747±36 ms (+40%, P&lt;0.0001), similar to the QT prolongation by <z:chebi fb="0" ids="4681">dofetilide</z:chebi> (511±22 to 703±45 ms [+38%, P&lt;0.0001]) </plain></SENT>
<SENT sid="7" pm="."><plain>AZD1305 slightly slowed the idioventricular rhythm </plain></SENT>
<SENT sid="8" pm="."><plain>Whereas <z:hpo ids='HP_0000001'>all</z:hpo> (n=14) <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001678'>atrioventricular block</z:hpo> animals exhibited <z:hpo ids='HP_0001664'>torsades de pointes</z:hpo> on <z:chebi fb="0" ids="4681">dofetilide</z:chebi>, the <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> was induced in only 4 of 11 dogs after AZD1305 </plain></SENT>
<SENT sid="9" pm="."><plain>Beat-to-beat variability of left-ventricular monophasic-action-potential duration increased after <z:chebi fb="0" ids="4681">dofetilide</z:chebi> (2.3±0.2 to 6.3±0.7 ms; P&lt;0.0001) but not after AZD1305 (2.8±0.3 to 3.7±0.3 ms; P=0.20) despite similar left-ventricular monophasic-action-potential duration prolongations </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Despite causing similar degrees of repolarization delay as the selective I(Kr) blocker <z:chebi fb="0" ids="4681">dofetilide</z:chebi>, the combined ion-channel blocker AZD1305 induces less repolarization instability and has a lower ventricular proarrhythmic potential in the remodeled dog heart </plain></SENT>
</text></document>